Skip to main content
Premium Trial:

Request an Annual Quote

Personalis NeXT Liquid Biopsy

Personalis has launched NeXT Liquid Biopsy, an exome-scale blood-based tumor-profiling assay for advanced-stage solid tumor cancer patients. According to the company, the test monitors over 20 times more genes than most targeted liquid biopsy panels on the market. Personalis believes its more comprehensive option can help biopharmaceutical companies advance their understanding of tumor biology, including resistance mechanisms, to aid in the development of next-generation cancer therapies. 
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.